Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biological response modifiers: preclinical evaluation and clinical activity.

R V Smalley, R K Oldham

    Critical Reviews in Oncology/Hematology
    |January 1, 1984
    PubMed
    Summary

    Biological response modifiers, including interferons and monoclonal antibodies, are emerging as promising tumor-specific therapies. Advances in genetic engineering enable the development of highly pure agents for preclinical and clinical trials, showing early efficacy in cancer treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen.

    Leukemia·2001
    Same author

    Growth of tumor-derived activated T cells for the treatment of advanced cancer.

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    "Historical Vignettes".

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    Cancer biotherapy: when, why and how long?

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    Fundamentally different.

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    Treatment of drug resistance: biotherapy or chemotherapy?

    Cancer biotherapy & radiopharmaceuticals·2000

    Area of Science:

    • Immunology
    • Oncology
    • Biotechnology

    Background:

    • Biological response modifiers (BRMs) are agents that modulate the host immune response against tumors.
    • These include interferons, lymphokines, tumor antigens, and antibodies, often derived from the human genome.
    • Advances in genetic engineering and monoclonal antibody technology allow for the production of highly purified BRMs.

    Purpose of the Study:

    • To discuss the development of biological response modifiers for cancer therapy.
    • To highlight the role of preclinical models in predicting clinical efficacy.
    • To review early clinical results and ongoing Phase II studies of BRMs.

    Main Methods:

    • Utilizing genetic engineering and monoclonal antibody technology for BRM production.

    Related Experiment Videos

  • Employing preclinical models to assess the activity of BRMs.
  • Conducting clinical trials, including Phase II studies, to evaluate efficacy in patients.

    • Main Results:

    • Highly purified interferons and monoclonal antibodies show potential for tumor-specific therapy.
    • BRMs, alone or conjugated to toxins, are progressing towards clinical application.
    • Early clinical data suggest responses in patients with detectable disease.

    Conclusions:

    • Biological response modifiers represent a significant advancement in anticancer strategies.
    • Continued development and testing are crucial for optimizing BRM therapy.
    • The potential for effective, targeted cancer treatment with BRMs is increasingly evident.